Customer Center
Login | Register

Yearly Archives: 2015

Severe Norovirus Outbreak Underscores Need for Rapid Testing

December 30th, 2015 / Nanosphere, A Luminex Company

A mass of norovirus cases linked to a Boston Chipotle this month is one of the biggest outbreaks of the virus in the US since 2009. To date, 80 illnesses have been confirmed by the Boston Public Health Commission, and another 140 Boston College students have come to the campus health center with suspected cases of norovirus.

The “Phantom Menace” Superbug Reveals Dark Side of Antibiotic Misuse

December 17th, 2015 / Nanosphere, A Luminex Company

Cases of a threatening superbug, nicknamed the “phantom menace,” are rising in the U.S., according to the Centers for Disease Control and Prevention (CDC). The phantom menace superbug produces OXA-48-like carbapenemases and has been observed most frequently in Enterobacteriaceae isolates. This type of carbapenem-resistant Enterobacteriaceae (CRE), however, has a lower level of resistance than other strains of CRE. As a result, these isolates have not been tested for and identified as frequently as other CREs and have widely escaped detection by health officials, earning it the nickname “phantom menace.”

Peer-to-Peer: Why Flexible Testing?

December 3rd, 2015 / Luminex Corporation

At last month’s Association for Molecular Pathology (AMP) Annual Meeting in Austin, TX, Margie Morgan, PhD, Scientific Director of Microbiology at Cedars-Sinai Medical Center in Los Angeles, CA, discussed the advantages of flexible multiplex tests over the currently available fixed-panel, fixed-price respiratory, and gastrointestinal tests. In her talk, Dr. Morgan described how flexible tests will

Continue reading »

Study Demonstrates Statistically Significant Reduction in 30-Day Mortality After Implementing Verigene BC-GP and BC-GN

November 25th, 2015 / Luminex Corporation

A new study from Tsukuba Medical Center Hospital in Tsukuba, Japan demonstrated statistically significant clinical and economic patient outcomes following the implementation of Verigene Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Tests.

WHO Launches Inaugural World Antibiotic Awareness Week

November 23rd, 2015 / Nanosphere, A Luminex Company

This Monday marked the start of the World Health Organization’s inaugural World Antibiotic Awareness Week, a campaign that aims to increase awareness of global antibiotic resistance and encourage best practices among the general public, health workers, policy-makers, and the agriculture sector to avoid the further emergence and spread of antibiotic resistance. The theme of this year’s campaign, “Antibiotics: Handle with Care,” reflects the idea that antibiotics are a precious resource that must be utilized sparingly and appropriately.

CRE Superbug an Increasing Threat Among Children

October 29th, 2015 / Luminex Corporation

A new study published this month in the Centers for Disease Control’s publication Emerging Infectious Diseases shows that children are acquiring highly fatal carbapenem-resistant Enterobacteriaceae (CRE) infections at a much higher rate than in the recent past.

Inappropriate Empiric Antibiotics Lengthen Hospitalization for Patients with Gram-Negative BSIs

October 22nd, 2015 / Nanosphere, A Luminex Company

In a study presented at IDWeek 2015 in San Diego, CA, Sara Cain, PharmD, and colleagues from University of South Carolina School of Medicine demonstrated that inappropriate empiric antibiotic treatment is associated with increased hospital length of stay (LOS) for patients with gram-negative bloodstream infections (BSI).

Getting Ready for Flu Season

October 16th, 2015 / Nanosphere, A Luminex Company

The fall season brings Americans cooler weather, football, pumpkin spice lattes, and, also, the dreaded flu. The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season. All of the available vaccine options this year were designed to protect against the following:

Luminex® miRNA Analysis Made Easy with a Multiplex miRNA Probe Design Tool

October 12th, 2015 / Stephen Angeloni

While a number of PCR based assays may be used for miRNA analysis, few are suitable for the economic analysis of large numbers of miRNAs in one reaction. Those that are capable of multiplexed analysis often lack the single base resolution needed to distinguish a number of miRNAs that differ by only one nucleotide base. The miRNA Chimeric Probe Design Tool will automatically assemble probe sequences in a near ready to order format. Of the 13 tabs in the file, the user only needs to use four of these tabs.

Four New Verigene Outcomes Studies to be Presented at IDWeek 2015

October 5th, 2015 / Luminex Corporation

Four new outcomes studies associated with implementation of Verigene® Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Tests will be presented during IDWeek 2015 in San Diego this week. These studies focus on the clinical impact that BC-GP and BC-GN paired with pharmacy and/or antimicrobial stewardship team (AST) intervention can have on optimization of antimicrobial therapy

Continue reading »